Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Convalescent Plasma EUA Will Not Complicate Hyperimmune Globulin Product Development, Sponsors Say

Aug 26 2020

• By Sue Sutter

Packages with donated plasma and blood — EUA may boost demand for convalescent plasma and competition for donors. • Source: Shutterstock

Related Content

Analyzing the Evidence For The Convalescent Plasma EUA

Aug 25 2020

Fate Of COVID-19 Convalescent Plasma Clinical Trials At Stake As US FDA Weighs EUA

Aug 21 2020

Preapproval Promotion? US FDA Commissioner Touts ‘Lifesaving’ Investigational Plasma For COVID-19

Aug 07 2020

US FDA COVID-19 Adcom: What Additional Members Are Needed?

Aug 17 2020

Plasma Authorization Raises Fears Of Politically-Influenced COVID-19 Vaccine Decisions, Compromised FDA

Aug 25 2020

US FDA To Exercise ‘Maximum Regulatory Flexibility’ For COVID-19 Plasma-Derived Therapeutics

Mar 25 2020

Takeda, CSL, Other Blood Plasma Firms Team On Hyperimmune COVID-19 Therapy

Apr 06 2020

Related Companies

Emergent BioSolutions, Inc.

Takeda Pharmaceutical Co. Ltd.

CSL Limited

ImmunoTek Bio Centers, LLC.

Additional Topics

United States Coronavirus COVID-19 Clinical Trials Research & Development Regulation Infectious Diseases BioPharmaceutical

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window